These Are 2 of The Biggest Issues with Healthcare AI, According to an FDA Reviewer

The US Food and Drugs Administration (FDA) has said it would like companies to conduct post-market monitoring in healthcare AI. Luke Ralston, a scientific reviewer for the agency, called for transparency as AI regulation evolves according to its specific use. Ralston said developers of healthcare AI models should ideally have tens of thousands of data points and that “performance drift” was among recurrent issues raised over AI’s deployment.